The Belgium-based cell therapy company Promethera Biosciences SA has raised €10 million from the Japanese conglomerate Itochu Corp as part of an ongoing Series D financing round to advance its portfolio of experimental medicines for chronic liver failure, nonalcoholic steatohepatitis (NASH) and fibrosis.
As part of the financing, Tajio Enoki, head of the medical business team in the energy and chemicals unit of Itochu, will join Promethera’s Board of Directors.